News and Announcements
Proteomics Investor Presentation August 2015
- Published August 20, 2015 11:50AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
20th August 2015, ASX Announcement
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd (PILL) (ASX: PIQ) is an emerging life science company focused on the area of proteomics, the industrial scale study of the structure and function of proteins. Proteomics is a key component of the biotechnology and life sciences industries and plays a vital role in understanding disease and biological systems, and the Company is recognised as a global leader in the field.
Its business model is based on its proprietary technology platform which operates across three synergistic business units in massive growth markets: analytical services, diagnostics and therapeutic drug discovery. The Company listed on the ASX in April 2015 after raising $3m in an IPO and the funds raised will be used to expand each business unit.
If you would like to read their Investor Presentation, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
